Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.

Abstract:

:This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol. At the end of a placebo baseline, patients were randomly assigned to placebo or one of three weight-adjusted imipramine dosages: low (0.5 mg/kg per day), medium (1.5 mg/kg per day), or high (3.0 mg/kg per day). It was demonstrated that imipramine had no significant effect on sitting or standing diastolic or systolic blood pressure. Although there was a trend toward a systolic blood pressure drop with positional change, it did not reach statistical significance. There were no significant changes in diastolic blood pressure with postural change. Imipramine did increase sitting and standing heart rate without revealing a clear dosage correlation. In contrast to the pretreated state, the reflex heart rate response to postural change was significantly increased in the posttreatment state, also in a dosage-independent manner. Within the high-dose imipramine group, the baseline sitting to standing heart rate increase was significantly higher in those who dropped out because of drug side effects compared with those who remained. Evidence from this study suggests that imipramine has a dosage-independent effect on resting and reflex heart rate. Future studies should consider postural heart rate reactivity as a potential measure of intolerance to the side effects of high doses of imipramine.

journal_name

J Clin Psychopharmacol

authors

de Groot CM,Mavissakalian MR

subject

Has Abstract

pub_date

1994-04-01 00:00:00

pages

107-10

issue

2

eissn

0271-0749

issn

1533-712X

journal_volume

14

pub_type

临床试验,杂志文章,随机对照试验
  • Antidepressant properties of anticonvulsant drugs for bipolar disorder.

    abstract::A growing number of anticonvulsant drugs are receiving attention as possible mood stabilizers. This attention is based mainly on the assumption that the antimanic efficacy of anticonvulsants makes them suitable as mood stabilizers. However, their antidepressant properties have received less scrutiny. In this review, c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-200304000-00011

    authors: Ernst CL,Goldberg JF

    更新日期:2003-04-01 00:00:00

  • Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics.

    abstract::Consensus guidelines which are applicable in New Zealand and worldwide recommend that the duration of exposure to antipsychotics not exceed 12 weeks, unless justified for mental illnesses like schizophrenia and severe psychotic symptoms which require longer treatment. There has been limited information on time-to-firs...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000597

    authors: Ndukwe HC,Nishtala PS

    更新日期:2016-12-01 00:00:00

  • Ongoing lithium treatment prevents relapse after total sleep deprivation.

    abstract::Forty bipolar depressed inpatients underwent three consecutive cycles of total sleep deprivation (TSD). At the beginning of the study, 20 patients were free of psychotropic drugs and 20 had been receiving lithium medication for at least 6 months. Mood was rated on the Hamilton Rating Scale for Depression before and af...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199906000-00007

    authors: Benedetti F,Colombo C,Barbini B,Campori E,Smeraldi E

    更新日期:1999-06-01 00:00:00

  • Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.

    abstract::Aripiprazole is widely used to treat schizophrenia. Plasma levels of aripiprazole and its active metabolite dehydroaripiprazole and their clinical responses in patients were explored. Forty-five (male/female: 19/26) patients with schizophrenia were treated with aripiprazole after a washout period of at least 3 days. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3182356255

    authors: Lin SK,Chen CK,Liu YL

    更新日期:2011-12-01 00:00:00

  • Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

    abstract::The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose m...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000416

    authors: McIntyre RS,Gorwood P,Thase ME,Liss C,Desai D,Chen J,Bauer M

    更新日期:2015-12-01 00:00:00

  • Role of newer medications for bipolar disorder.

    abstract::The quest for additional effective therapies for bipolar study commenced in the 1960s, even before regulatory approval of lithium. This was driven by the recognition that patient response to lithium varied from excellent to poor; thus, significant numbers of patients faced its frequent adverse effects and risks withou...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199604001-00006

    authors: Bowden CL

    更新日期:1996-04-01 00:00:00

  • Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.

    abstract::The objective of this study was to compare the efficacy of the alpha-2a agonist guanfacine with that of dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD). Seventeen adult outpatients who met DSM-IV criteria for ADHD participated in a double-blind, placebo-controlled, crossove...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200104000-00015

    authors: Taylor FB,Russo J

    更新日期:2001-04-01 00:00:00

  • Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.

    abstract::The selective serotonin reuptake inhibitor antidepressant fluoxetine inhibits alprazolam metabolism in vivo by inhibition of the cytochrome P450 3A4 enzyme. Citalopram is a selective serotonin reuptake inhibitor antidepressant that has not yet been fully evaluated with respect to its potential for cytochrome P450 3A4-...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000085407.08426.e1

    authors: Hall J,Naranjo CA,Sproule BA,Herrmann N

    更新日期:2003-08-01 00:00:00

  • Psychiatric reactions during tricyclic treatment of the elderly reconsidered.

    abstract::In a prospective study of all geriatric patients treated with tricyclic antidepressants over an 18-month period, a lower incidence of adverse psychiatric reactions than literature based on chart reviews has suggested was found. In only three of the 43 patients studied (7%) did a picture consistent with toxic delirium ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Meyers BS,Mei-Tal V

    更新日期:1983-02-01 00:00:00

  • Longitudinally Measured Changes in Somnolence Severity With a Visual Analog Scale in a Randomized Lithium Versus Quetiapine-IR Study in Bipolar Disorder.

    abstract:OBJECTIVE:The aim of this study was to use a visual analog scale (VAS) longitudinally measuring somnolence severity in patients with bipolar disorder. METHODS:A data set of patients with bipolar spectrum disorders who were randomized to lithium or quetiapine-IR for 16 weeks was used. The somnolence severity was measur...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000001031

    authors: Gao K,Su M,Ganocy SJ,Goto T,Yuan C,Fang F,Conroy C,Brownrigg B,Serrano MB,Calabrese JR

    更新日期:2019-05-01 00:00:00

  • The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.

    abstract:BACKGROUND:The combination of olanzapine and valproic acid (VPA) is regularly prescribed in the treatment of bipolar or schizoaffective disorders. The VPA has been shown to reduce olanzapine concentration, but the mechanism behind this interaction remains unknown. We aimed to investigate the effect of VPA on olanzapine...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001126

    authors: Tveito M,Smith RL,Høiseth G,Molden E

    更新日期:2019-11-01 00:00:00

  • Review of the use of topiramate for treatment of bipolar disorders.

    abstract::Lithium alone or in combination with other psychotherapeutic drugs has long been the gold standard of management for bipolar disorder (BD). Recognition of its limitations in the acute and chronic management of BD has led to the development of alternative therapies. One such approach involves the use of antiepileptic d...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-200212000-00010

    authors: Suppes T

    更新日期:2002-12-01 00:00:00

  • Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.

    abstract::Results of previous studies on the safety of antidepressants during pregnancy have been conflicting. The primary objective of this study was to investigate whether first-trimester exposure to antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), was associated with increased risk of congenital...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182490eaf

    authors: Nordeng H,van Gelder MM,Spigset O,Koren G,Einarson A,Eberhard-Gran M

    更新日期:2012-04-01 00:00:00

  • Pharmacokinetics of valproate and carbamazepine.

    abstract::Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use. Much of the information has been gained through their use as successful antiepileptic medications. As these agents begin to play an increasing role as mood-s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199202001-00010

    authors: Wilder BJ

    更新日期:1992-02-01 00:00:00

  • Nifedipine in the treatment of tardive dyskinesia.

    abstract::There have been several case reports of improvement in tardive dyskinesia (TD) after treatment with calcium-blocking agents. We have conducted prior single-blind (rater-blind) studies of verapamil and diltiazem and found a statistically significant improvement in TD with verapamil, and a small improvement that did not...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199010060-00006

    authors: Duncan E,Adler L,Angrist B,Rotrosen J

    更新日期:1990-12-01 00:00:00

  • St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study.

    abstract::Recognition of social anxiety disorder (social phobia) as a common and disabling condition has led to new advances in its pharmacotherapy. Limitations with selective seroton reuptake inhibitors (side effects) and behavior therapy (scarcity of trained therapists), coupled with the tendency for patients with the disorde...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000150227.61501.00

    authors: Kobak KA,Taylor LV,Warner G,Futterer R

    更新日期:2005-02-01 00:00:00

  • Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.

    abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nagy LM,Krystal JH,Charney DS,Merikangas KR,Woods SW

    更新日期:1993-02-01 00:00:00

  • Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort.

    abstract::This study aimed to assess whether exposure to anticholinergic and sedative medications and its evolution was associated with increased risk of in-hospital falls and all-cause mortality. Furthermore, results were compared with 2 definitions of drug burden index (DBI) against the outcomes.This observational, multicentr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/JCP.0000000000000195

    authors: Dauphinot V,Faure R,Omrani S,Goutelle S,Bourguignon L,Krolak-Salmon P,Mouchoux C

    更新日期:2014-10-01 00:00:00

  • Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.

    abstract::Plasma and red blood cell levels of haloperidol, thioridazine, and thioridazine's main metabolite mesoridazine were measured in schizophrenic outpatients during treatment with fixed doses of haloperidol or thioridazine for several months. These drug levels were compared to those in schizophrenic inpatients treated wit...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Shvartsburd A,Sajadi C,Morton V,Mirabi M,Gordon J,Smith RC

    更新日期:1984-08-01 00:00:00

  • Inhibition of CYP2D6 activity by bupropion.

    abstract::The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000162805.46453.e3

    authors: Kotlyar M,Brauer LH,Tracy TS,Hatsukami DK,Harris J,Bronars CA,Adson DE

    更新日期:2005-06-01 00:00:00

  • Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.

    abstract::As many as 45% of patients with major depression also meet diagnostic criteria for bipolar (BP) II disorder. Although the use of a concurrent mood-stabilizing drug has been suggested in treating BP II depression, antidepressant monotherapy has received less attention. The efficacy and safety of venlafaxine were examin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199810000-00010

    authors: Amsterdam J

    更新日期:1998-10-01 00:00:00

  • Specific side effects of long-term imipramine management of panic disorder.

    abstract::In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2.25 mg/kg/day. Although sexual dysfunction and weight...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200204000-00008

    authors: Mavissakalian M,Perel J,Guo S

    更新日期:2002-04-01 00:00:00

  • Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.

    abstract::Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenic patients. After a 2- to 9-day placebo lead-in, 79 inpatients with schizophrenia according to DSM-III-R criteria were placed on an olanzapine dosage of 10 mg/day or 1 mg/day for up to 6 weeks. Blood samples were obtained weekly during t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00004714-199712000-00006

    authors: Perry PJ,Sanger T,Beasley C

    更新日期:1997-12-01 00:00:00

  • Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

    abstract:BACKGROUND:Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluati...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000766

    authors: Foster A,Buckley P,Lauriello J,Looney S,Schooler N

    更新日期:2017-10-01 00:00:00

  • The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.

    abstract::In this study, the authors investigated the relationship between the metabolism of clomipramine (C) and the genotypes of cytochrome P450 (CYP) CYP2C19 and CYP2D6. Fifty-one Japanese patients (18 men and 33 women) were administered 10 to 250 mg/day of C by mouth and maintained on the same daily dose of C for at least 2...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200112000-00002

    authors: Yokono A,Morita S,Someya T,Hirokane G,Okawa M,Shimoda K

    更新日期:2001-12-01 00:00:00

  • Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.

    abstract::Quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) for the treatment of mania was evaluated in 2 double-blind, placebo-controlled studies. Patients were randomized to 3 or 6 weeks of treatment with QTP plus Li/DVP or placebo (PBO) plus Li/DVP. Quetiapine was dosed up to 800 mg/d; Li was dosed to achieve s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000144887.66319.2f

    authors: Yatham LN,Paulsson B,Mullen J,Vågerö AM

    更新日期:2004-12-01 00:00:00

  • Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.

    abstract::The aim of this study was to estimate the long-term effectiveness of olanzapine as adjunctive therapy in patients with bipolar disorder who exhibited an inadequate response to mood stabilizers. Twenty-three Research Diagnostic Criteria (RDC) patients with bipolar I and II were assessed by means of the Schedule for Aff...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200110000-00002

    authors: Vieta E,Reinares M,Corbella B,Benabarre A,Gilaberte I,Colom F,Martínez-Arán A,Gastó C,Tohen M

    更新日期:2001-10-01 00:00:00

  • Sex selection bias in schizophrenia antipsychotic trials.

    abstract::The sex prevalence of schizophrenia is approximately equal, and yet clinical trials of new therapeutic drugs have been conducted, for the most part, with male participants. The authors reviewed the percentage of women in schizophrenia clinical trials of the new "atypical" antipsychotic medications. MEDLINE and Cochran...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.jcp.0000236652.78168.ee

    authors: Chaves AC,Seeman MV

    更新日期:2006-10-01 00:00:00

  • Symptom comorbidity in anxiety and depressive disorders.

    abstract::The ability of the Hamilton Rating Scale for Anxiety, the Hamilton Rating Scale for Depression, and 50 items from the self-rated Hopkins Symptom Checklist to discriminate generalized anxiety disorder from major depressive disorder was examined for over 3,000 patients entering studies in three drug development projects...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199006001-00011

    authors: Copp JE,Schwiderski UE,Robinson DS

    更新日期:1990-06-01 00:00:00

  • Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.

    abstract::An antidepressant for use in the patient receiving concomitant drug treatment, over-the-counter medications, or herbal products should lack cytochrome P-450 (CYP) 3A4 inductive or inhibitory activity to provide the least likelihood of a drug-drug interaction. This study addresses the potential of 4 diverse antidepress...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000104908.75206.26

    authors: DeVane CL,Donovan JL,Liston HL,Markowitz JS,Cheng KT,Risch SC,Willard L

    更新日期:2004-02-01 00:00:00